Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 15 |
| Active Pipeline (Recruiting Now) | 5 (2) |
| Completed vs Stopped Early | 2 / 7 (46.7%) |
| Median Closed Actual Enrollment | 24 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Universitätsklinikum Hamburg-Eppendorf | Hamburg | 3 |
| Universitätsklinikum Freiburg | Freiburg im Breisgau, Baden-Wurttemberg | 3 |
| Universitätsklinikum Tübingen | Tübingen | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05675319 | Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma A | Phase III | TERMINATED |
Explore interactive annual charts and M&A subsidiary rollups in the Universitätsklinikum Hamburg-Eppendorf Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.